Context Therapeutics Inc.

For the period ended Mar 31, 2025. Filed May 7, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 7, 2025

CNTX$0.19-6.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Cash Flows

	Three months ended March 31,
	2025	2024
Cash flows from operating activities:
Net loss	$(4,577,261)	$(3,667,797)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense	293,717	240,007
Depreciation and amortization expense	4,055	2,568
Reduction in the carrying amount of operating lease right-of-use asset	26,012	—
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	87,560	647,895
Accounts payable	(435,637)	(337,652)
Accrued expenses and other current liabilities	(401,153)	(1,245,641)
Operating lease liability	(25,674)	—
Cash used in operating activities	(5,028,381)	(4,360,620)
Cash flows from investing activities:
Purchase of property and equipment	(33,948)	—
Cash used in investing activities	(33,948)	—
Cash flows from financing activities:
Payment of offering costs from the sale of common stock from ATM facility	(15,268)	—
Cash used in financing activities	(15,268)	—
Net decrease in cash and cash equivalents	(5,077,597)	(4,360,620)
Cash and cash equivalents at beginning of period	94,429,824	14,449,827
Cash and cash equivalents at end of period	$89,352,227	$10,089,207

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.